/PRNewswire/ MimiVax is pleased to announce the published manuscript of the now completed Phase IIa study of SurVaxM, a cancer vaccine, in newly diagnosed.
To honor David Berndt and to shine a light on the power of art, the cancer center is displaying a collection of his images in its Community Artists Gallery.